CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial Prevention, Diagnosis, and Management of Radiation-Associated Cardiac Disease: JACC Scientific Expert Panel Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque Thirty-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Results The Year in Cardiovascular Medicine 2020: Coronary Prevention: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of coronary prevention is Professor Ramon Estruch, Dr Luis Ruilope, and Professor Francesco Cosentino. Mark Nicholls meets them Intravascular Ultrasound Assessment of In-Stent Restenosis in Saphenous Vein Grafts Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Clinical TrialDecember 8, 2020 Vol 142, Issue 23

JOURNAL:Circulation. Article Link

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial

F Cosentino , CP Cannon , DZI Cherney et al. Keywords: ertugliflozin;T2DM; ASCVD, HF

Full Text PDF